$AVAH
Aveanna Healthcare Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056215 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $505.0M $490.7M
YoY Change 8.26%
Cost Of Revenue $346.7M $344.8M
YoY Change 7.69%
Gross Profit $158.3M $145.9M
YoY Change 9.55%
Gross Profit Margin 31.34% 29.73%
Selling, General & Admin $87.97M $87.91M
YoY Change -4.07%
% of Gross Profit 55.58% 60.28%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.833M $2.912M
YoY Change -29.89%
% of Gross Profit 1.79% 2.0%
Operating Expenses $87.97M $87.91M
YoY Change -4.07%
Operating Profit $37.13M $22.87M
YoY Change 110.48%
Interest Expense $39.61M $39.65M
YoY Change 10.16%
% of Operating Profit 106.7% 173.39%
Other Income/Expense, Net $6.371M $18.17M
YoY Change -152.27%
Pretax Income $3.979M $1.490M
YoY Change -113.08%
Income Tax -$9.900M $12.70M
% Of Pretax Income -248.81% 852.35%
Net Earnings $13.91M -$11.17M
YoY Change -143.46%
Net Earnings / Revenue 2.75% -2.28%
Basic Earnings Per Share $0.07 -$0.06
Diluted Earnings Per Share $0.07 -$0.06
COMMON SHARES
Basic Shares Outstanding 192.4M 192.4M
Diluted Shares Outstanding 196.9M 192.2M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.66M $42.61M
YoY Change 38.42%
Cash & Equivalents $47.66M $42.61M
Short-Term Investments
Other Short-Term Assets $14.59M $8.831M
YoY Change 34.58%
Inventory
Prepaid Expenses $16.80M $16.03M
Receivables $273.0M $257.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $364.0M $336.0M
YoY Change 17.99%
LONG-TERM ASSETS
Property, Plant & Equipment $19.23M $19.42M
YoY Change -10.34%
Goodwill $1.055B $1.055B
YoY Change -9.07%
Intangibles $92.86M $93.36M
YoY Change -4.79%
Long-Term Investments
YoY Change
Other Assets $64.06M $66.90M
YoY Change -5.18%
Total Long-Term Assets $1.300B $1.307B
YoY Change -8.57%
TOTAL ASSETS
Total Short-Term Assets $364.0M $336.0M
Total Long-Term Assets $1.300B $1.307B
Total Assets $1.664B $1.643B
YoY Change -3.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $39.12M $43.18M
YoY Change -8.14%
Accrued Expenses $87.25M $84.39M
YoY Change 11.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.200M $9.200M
YoY Change 0.0%
Total Short-Term Liabilities $389.1M $381.9M
YoY Change 3.57%
LONG-TERM LIABILITIES
Long-Term Debt $1.274B $1.275B
YoY Change -0.46%
Other Long-Term Liabilities $4.532M $3.803M
YoY Change 1343.31%
Total Long-Term Liabilities $1.278B $1.279B
YoY Change -0.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $389.1M $381.9M
Total Long-Term Liabilities $1.278B $1.279B
Total Liabilities $1.782B $1.777B
YoY Change 0.98%
SHAREHOLDERS EQUITY
Retained Earnings -$1.369B -$1.382B
YoY Change 7.87%
Common Stock $1.250B $1.246B
YoY Change 1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$119.0M -$136.3M
YoY Change
Total Liabilities & Shareholders Equity $1.664B $1.643B
YoY Change -3.84%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $13.91M -$11.17M
YoY Change -143.46%
Depreciation, Depletion And Amortization $2.833M $2.912M
YoY Change -29.89%
Cash From Operating Activities $1.809M -$11.97M
YoY Change -75.86%
INVESTING ACTIVITIES
Capital Expenditures $1.269M $1.308M
YoY Change -40.2%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.269M -$1.308M
YoY Change -73.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.514M 11.95M
YoY Change -63.95%
NET CHANGE
Cash From Operating Activities 1.809M -11.97M
Cash From Investing Activities -1.269M -1.308M
Cash From Financing Activities 4.514M 11.95M
Net Change In Cash 5.054M -1.335M
YoY Change -66.78%
FREE CASH FLOW
Cash From Operating Activities $1.809M -$11.97M
Capital Expenditures $1.269M $1.308M
Free Cash Flow $540.0K -$13.28M
YoY Change -89.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40362
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-28
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001832332
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-30
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Aveanna Healthcare Holdings Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4717209
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
400 Interstate North Parkway SE
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30339
CY2024Q1 dei City Area Code
CityAreaCode
770
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
441-1580
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
AVAH
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
192378711
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42607000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43942000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
257544000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
236558000
CY2024Q1 avah Receivables Under Insured Programs Current
ReceivablesUnderInsuredProgramsCurrent
11024000
CY2023Q4 avah Receivables Under Insured Programs Current
ReceivablesUnderInsuredProgramsCurrent
9250000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16030000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15684000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
8831000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9452000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
336036000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
314886000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19424000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20548000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47686000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49499000
CY2024Q1 us-gaap Goodwill
Goodwill
1054552000
CY2023Q4 us-gaap Goodwill
Goodwill
1054552000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
93364000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
94010000
CY2024Q1 avah Receivables Under Insured Programs Noncurrent
ReceivablesUnderInsuredProgramsNoncurrent
24991000
CY2023Q4 avah Receivables Under Insured Programs Noncurrent
ReceivablesUnderInsuredProgramsNoncurrent
21315000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66899000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58175000
CY2024Q1 us-gaap Assets
Assets
1642952000
CY2023Q4 us-gaap Assets
Assets
1612985000
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
43175000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
30130000
CY2024Q1 avah Accrued Payroll And Employee Benefits
AccruedPayrollAndEmployeeBenefits
68953000
CY2023Q4 avah Accrued Payroll And Employee Benefits
AccruedPayrollAndEmployeeBenefits
67160000
CY2024Q1 avah Current Portion Of Insurance Reserves Insured Programs
CurrentPortionOfInsuranceReservesInsuredPrograms
11024000
CY2023Q4 avah Current Portion Of Insurance Reserves Insured Programs
CurrentPortionOfInsuranceReservesInsuredPrograms
9250000
CY2024Q1 avah Current Portion Of Insurance Reserves
CurrentPortionOfInsuranceReserves
20258000
CY2023Q4 avah Current Portion Of Insurance Reserves
CurrentPortionOfInsuranceReserves
20918000
CY2024Q1 avah Securitization Obligations
SecuritizationObligations
165000000
CY2023Q4 avah Securitization Obligations
SecuritizationObligations
155000000
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
9200000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
9200000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15440000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14881000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48880000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48219000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
381930000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
354758000
CY2024Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1275127000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1276341000
CY2024Q1 avah Long Term Insurance Reserves Insured Programs
LongTermInsuranceReservesInsuredPrograms
24991000
CY2023Q4 avah Long Term Insurance Reserves Insured Programs
LongTermInsuranceReservesInsuredPrograms
21315000
CY2024Q1 avah Long Term Insurance Reserves
LongTermInsuranceReserves
46629000
CY2023Q4 avah Long Term Insurance Reserves
LongTermInsuranceReserves
40290000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
39137000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
39818000
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5473000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4859000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3803000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3039000
CY2024Q1 us-gaap Liabilities
Liabilities
1777090000
CY2023Q4 us-gaap Liabilities
Liabilities
1740420000
CY2024Q1 avah Deferred Restricted Stock Units
DeferredRestrictedStockUnits
2135000
CY2023Q4 avah Deferred Restricted Stock Units
DeferredRestrictedStockUnits
2135000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
192378711
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
192378711
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
190733153
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
190733153
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1923000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1907000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1244210000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1239757000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1382406000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1371234000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-136273000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-129570000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1642952000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1612985000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
490653000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
466413000
CY2024Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
344799000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
321948000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
87914000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91708000
CY2024Q1 avah Corporate Expenses
CorporateExpenses
29842000
CY2023Q2 avah Corporate Expenses
CorporateExpenses
30935000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2912000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4041000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
70000
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2320000
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-72000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
22866000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
17639000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
102000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000
CY2024Q1 us-gaap Interest Expense
InterestExpense
39647000
CY2023Q2 us-gaap Interest Expense
InterestExpense
35958000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18169000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12188000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1490000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30432000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12662000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1566000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11172000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31998000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
192241000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192241000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189054000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189054000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-129570000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1349000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3120000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11172000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-136273000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6310000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2442000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31998000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35866000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-11172000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-31998000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2912000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4041000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1223000
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1421000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6233000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4236000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4081000
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2442000
CY2024Q1 avah Gain Loss On Disposition Or Impairment Of Licenses Property And Equipment And Internal Use Software
GainLossOnDispositionOrImpairmentOfLicensesPropertyAndEquipmentAndInternalUseSoftware
-229000
CY2023Q2 avah Gain Loss On Disposition Or Impairment Of Licenses Property And Equipment And Internal Use Software
GainLossOnDispositionOrImpairmentOfLicensesPropertyAndEquipmentAndInternalUseSoftware
-68000
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8276000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-18537000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
614000
CY2023Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
594000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20986000
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20595000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
346000
CY2023Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1500000
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4308000
CY2023Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4441000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13065000
CY2023Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1763000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1793000
CY2023Q2 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
18316000
CY2024Q1 us-gaap Increase Decrease In Self Insurance Reserve
IncreaseDecreaseInSelfInsuranceReserve
5679000
CY2023Q2 us-gaap Increase Decrease In Self Insurance Reserve
IncreaseDecreaseInSelfInsuranceReserve
1960000
CY2024Q1 avah Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4542000
CY2023Q2 avah Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1005000
CY2024Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1829000
CY2023Q2 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-17182000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11972000
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7495000
CY2023Q2 avah Purchase Of Certificates Of Need
PurchaseOfCertificatesOfNeed
2678000
CY2024Q1 avah Payments To Acquire Property Plant And Equipment And Internal Use Software
PaymentsToAcquirePropertyPlantAndEquipmentAndInternalUseSoftware
1308000
CY2023Q2 avah Payments To Acquire Property Plant And Equipment And Internal Use Software
PaymentsToAcquirePropertyPlantAndEquipmentAndInternalUseSoftware
2122000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1308000
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4800000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1349000
CY2024Q1 us-gaap Proceeds From Accounts Receivable Securitization
ProceedsFromAccountsReceivableSecuritization
20000000
CY2023Q2 us-gaap Proceeds From Accounts Receivable Securitization
ProceedsFromAccountsReceivableSecuritization
35000000
CY2024Q1 us-gaap Repayments Of Accounts Receivable Securitization
RepaymentsOfAccountsReceivableSecuritization
10000000
CY2023Q2 us-gaap Repayments Of Accounts Receivable Securitization
RepaymentsOfAccountsReceivableSecuritization
20000000
CY2023Q2 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
20000000
CY2023Q2 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
20000000
CY2024Q1 avah Repayment Of Term Loans
RepaymentOfTermLoans
2300000
CY2023Q2 avah Repayment Of Term Loans
RepaymentOfTermLoans
2300000
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1383000
CY2023Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3192000
CY2024Q1 avah Payments Of Financing Lease Obligations
PaymentsOfFinancingLeaseObligations
65000
CY2023Q2 avah Payments Of Financing Lease Obligations
PaymentsOfFinancingLeaseObligations
206000
CY2024Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
-4344000
CY2023Q2 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
-3219000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11945000
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12521000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1335000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15216000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43942000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19217000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42607000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34433000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
38491000
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
24196000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-64000
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-386000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_to_unaudited_consolidated_financia" style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. DESCRIPTION</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OF BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aveanna Healthcare Holdings Inc. (together with its consolidated subsidiaries, referred to herein as the “Company”) is headquartered in Atlanta, Georgia and has locations in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> states with concentrations in California, Texas and Pennsylvania, providing a broad range of pediatric and adult healthcare services including nursing, hospice, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.</span></p>
CY2024Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
33
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1314750000
CY2024Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
28123000
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
29209000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
1284327000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1285541000
CY2024Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
-4344000
CY2023Q2 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
-3219000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11945000
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12521000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1335000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15216000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43942000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19217000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42607000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34433000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
38491000
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
24196000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-64000
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-386000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_to_unaudited_consolidated_financia" style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. DESCRIPTION</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OF BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aveanna Healthcare Holdings Inc. (together with its consolidated subsidiaries, referred to herein as the “Company”) is headquartered in Atlanta, Georgia and has locations in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> states with concentrations in California, Texas and Pennsylvania, providing a broad range of pediatric and adult healthcare services including nursing, hospice, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.</span></p>
CY2024Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
33
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9200000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9200000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1275127000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1275127000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1276341000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s accounting and reporting policies conform with U.S. GAAP. In preparing the interim unaudited consolidated financial statements, the Company is required to make estimates and assumptions that impact the amounts reported in these interim unaudited consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></p>
CY2024Q1 avah Estimated Contractual Adjustments And Price Concessions
EstimatedContractualAdjustmentsAndPriceConcessions
68500000
CY2023Q4 avah Estimated Contractual Adjustments And Price Concessions
EstimatedContractualAdjustmentsAndPriceConcessions
62600000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1312450000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s accounting and reporting policies conform with U.S. GAAP. In preparing the interim unaudited consolidated financial statements, the Company is required to make estimates and assumptions that impact the amounts reported in these interim unaudited consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></p>
CY2024Q1 avah Estimated Contractual Adjustments And Price Concessions
EstimatedContractualAdjustmentsAndPriceConcessions
68500000
CY2023Q4 avah Estimated Contractual Adjustments And Price Concessions
EstimatedContractualAdjustmentsAndPriceConcessions
62600000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1312450000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1314750000
CY2024Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
28123000
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
29209000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
1284327000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1285541000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9200000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9200000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1276341000
CY2024Q1 avah Swingline Loan
SwinglineLoan
0
CY2023Q4 avah Swingline Loan
SwinglineLoan
0
CY2024Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1212000000
CY2024Q1 us-gaap Derivative Assets
DerivativeAssets
61753000
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
53477000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12700000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
8.498
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.051
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Malpractice Insurance Deductible1
MalpracticeInsuranceDeductible1
2000000
CY2022Q4 us-gaap Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
4500000
CY2024Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
102900000
CY2023Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
91800000
CY2024Q1 us-gaap Loss Contingency Name Of Defendant
LossContingencyNameOfDefendant
Epic/Freedom, LLC (“Seller”), Webster Capital Corporation, and Webster Equity Partners (collectively, the “Defendants”)
CY2020Q3 us-gaap Escrow Deposit
EscrowDeposit
7100000
CY2023Q2 us-gaap Escrow Deposit
EscrowDeposit
6800000
CY2023Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
7900000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189054000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189054000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2024Q1 avah Swingline Loan
SwinglineLoan
0
CY2023Q4 avah Swingline Loan
SwinglineLoan
0
CY2024Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1212000000
CY2024Q1 us-gaap Derivative Assets
DerivativeAssets
61753000
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
53477000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12700000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
8.498
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.051
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Malpractice Insurance Deductible1
MalpracticeInsuranceDeductible1
2000000
CY2022Q4 us-gaap Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
4500000
CY2024Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
102900000
CY2023Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
91800000
CY2024Q1 us-gaap Loss Contingency Name Of Defendant
LossContingencyNameOfDefendant
Epic/Freedom, LLC (“Seller”), Webster Capital Corporation, and Webster Equity Partners (collectively, the “Defendants”)
CY2020Q3 us-gaap Escrow Deposit
EscrowDeposit
7100000
CY2023Q2 us-gaap Escrow Deposit
EscrowDeposit
6800000
CY2023Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
7900000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189054000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189054000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
490653000
CY2024Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
344799000
CY2024Q1 us-gaap Gross Profit
GrossProfit
145854000
CY2024Q1 avah Gross Margin Percentage
GrossMarginPercentage
0.297
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
466413000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
321948000
CY2023Q2 us-gaap Gross Profit
GrossProfit
144465000
CY2023Q2 avah Gross Margin Percentage
GrossMarginPercentage
0.31
CY2024Q1 us-gaap Gross Profit
GrossProfit
145854000
CY2023Q2 us-gaap Gross Profit
GrossProfit
144465000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
87914000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91708000
CY2024Q1 avah Corporate Expenses
CorporateExpenses
29842000
CY2023Q2 avah Corporate Expenses
CorporateExpenses
30935000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2912000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4041000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
70000
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2320000
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-72000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
22866000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
17639000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
102000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000
CY2024Q1 us-gaap Interest Expense
InterestExpense
39647000
CY2023Q2 us-gaap Interest Expense
InterestExpense
35958000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18169000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12188000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1490000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30432000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11172000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31998000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
192241000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192241000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
490653000
CY2024Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
344799000
CY2024Q1 us-gaap Gross Profit
GrossProfit
145854000
CY2024Q1 avah Gross Margin Percentage
GrossMarginPercentage
0.297
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
466413000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
321948000
CY2023Q2 us-gaap Gross Profit
GrossProfit
144465000
CY2023Q2 avah Gross Margin Percentage
GrossMarginPercentage
0.31
CY2024Q1 us-gaap Gross Profit
GrossProfit
145854000
CY2023Q2 us-gaap Gross Profit
GrossProfit
144465000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
87914000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91708000
CY2024Q1 avah Corporate Expenses
CorporateExpenses
29842000
CY2023Q2 avah Corporate Expenses
CorporateExpenses
30935000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2912000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4041000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
70000
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2320000
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-72000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
22866000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
17639000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
102000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000
CY2024Q1 us-gaap Interest Expense
InterestExpense
39647000
CY2023Q2 us-gaap Interest Expense
InterestExpense
35958000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18169000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12188000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1490000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30432000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11172000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31998000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
192241000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192241000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 avah Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q3 avah Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 avah Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q3 avah Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-056215-index-headers.html Edgar Link pending
0000950170-24-056215-index.html Edgar Link pending
0000950170-24-056215.txt Edgar Link pending
0000950170-24-056215-xbrl.zip Edgar Link pending
avah-20240330.htm Edgar Link pending
avah-20240330.xsd Edgar Link pending
avah-ex31_1.htm Edgar Link pending
avah-ex31_2.htm Edgar Link pending
avah-ex31_3.htm Edgar Link pending
avah-ex32_1.htm Edgar Link pending
avah-ex32_2.htm Edgar Link pending
avah-ex32_3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img24670257_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
avah-20240330_htm.xml Edgar Link completed